Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two drugs, sodium bicarbonate and ondansetron. Sodium bicarbonate is an alkalinizing agent used to treat metabolic acidosis and certain drug intoxications by increasing plasma bicarbonate, buffering excess hydrogen ion concentration, and raising blood pH. Ondansetron is a selective serotonin 5-HT3 receptor antagonist primarily used as an antiemetic to prevent nausea and vomiting associated with chemotherapy, radiation therapy, or surgery. The combination does not have a unique brand name or established clinical use as a fixed-dose product; it may be considered for co-administration in specific clinical scenarios but lacks evidence of routine combined use. There are concerns about physical incompatibility when mixing these agents due to the alkaline nature of sodium bicarbonate potentially causing precipitation of ondansetron[3]. No direct pharmacological interaction has been reported between the two drugs[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium bicarbonate + ondansetron.